Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

NCT00528437 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT00528437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00528437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
December 30, 2017
Enrollment
46 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumors